© 2019 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
Phase III study misses statistical threshold, but the immunotherapy appears to show some benefit.
Keytruda showed modest benefits for people with hepatocellular carcinoma, and combining Opdivo with Yervoy improved outcomes.
Keytruda and Opdivo showed antitumor activity in some patients and acceptable side effects in real-world use.
Seventy percent of liver cancer patients had either a partial response or stable disease.
A third of patients taking neoadjuvant Opdivo had complete responses in an early analysis.
Half of people with worse liver function responded well to immunotherapy.
A second immunotherapy option is now available for hepatocellular carcinoma.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
